Summary
Amgen Inc. reported solid financial performance for the third quarter of 2013, demonstrating robust revenue and net income growth compared to the prior year. Total revenues increased by 10% year-over-year to $4.75 billion, driven primarily by strong product sales, particularly from key brands like Neulasta/Neupogen, Enbrel, Xgeva, and Prolia. Net income saw a significant jump of 24% to $1.37 billion, resulting in diluted Earnings Per Share (EPS) of $1.79, up from $1.41 in the same period last year. The company highlighted its ongoing strategic initiatives, including continued investment in research and development and the significant acquisition of Onyx Pharmaceuticals completed in early October 2013 for approximately $9.7 billion. This acquisition is expected to bolster Amgen's oncology franchise. Amgen also continues to return capital to shareholders through dividends and has a substantial repurchase program in place, although no shares were repurchased in the second or third quarters of 2013. The company maintains a strong liquidity position, with substantial cash and marketable securities, though it has also increased its long-term debt to finance strategic initiatives.
Financial Highlights
55 data points| Revenue | $4.75B |
| Cost of Revenue | $788.00M |
| Gross Profit | $3.86B |
| SG&A Expenses | $1.25B |
| Operating Expenses | $3.06B |
| Operating Income | $1.69B |
| Interest Expense | $257.00M |
| Net Income | $1.37B |
| EPS (Basic) | $1.81 |
| EPS (Diluted) | $1.79 |
| Shares Outstanding (Basic) | 754.00M |
| Shares Outstanding (Diluted) | 766.00M |
Key Highlights
- 1Total revenues for the third quarter of 2013 increased by 10% to $4.75 billion, with product sales growing 11% year-over-year.
- 2Net income rose significantly by 24% to $1.37 billion, and diluted EPS increased to $1.79 from $1.41 in the prior year's third quarter.
- 3Key products like Neulasta/Neupogen, Enbrel, Xgeva, and Prolia showed strong sales growth, contributing significantly to the revenue increase.
- 4Amgen completed the acquisition of Onyx Pharmaceuticals in early October 2013 for approximately $9.7 billion, significantly expanding its oncology portfolio.
- 5The company maintained a strong balance sheet with $8.28 billion in cash and cash equivalents and $14.28 billion in marketable securities as of September 30, 2013.
- 6Amgen continued to return capital to shareholders with a quarterly dividend of $0.47 per share, and had $1.6 billion remaining under its stock repurchase program.
- 7Research and Development (R&D) expenses increased by 12% to $989 million, reflecting continued investment in pipeline development, including significant costs for evolocumab and the upfront payment for ivabradine rights.